Major clinical research advances in gynecologic cancer in 2014

Journal of Gynecologic Oncology

Volumn 26, Issue 2, 2015, Pages 156-167

  Suh, Dong Hoon ^a   Lee, Kyung Hun ^b   Kim, Kidong ^a   Kang, Sokbom ^c   Kim, Jae Weon ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

Angiogenesis inhibitor; Breast neoplasm; Early detection of cancer; Leiomyosarcoma; Ovarian neoplasm; Poly (ADP ribose) polymerase

Indexed keywords

BEVACIZUMAB; CEDIRANIB; EXEMESTANE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PAZOPANIB; TAMOXIFEN; Z 100;

ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL RESEARCH; DRUG EFFICACY; EARLY CANCER; ENDOMETRIUM CANCER; EUROPE; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GYNECOLOGIC CANCER; GYNECOLOGIC SURGERY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TUMOR INFILTRATING LYMPHOCYTE; MAINTENANCE CHEMOTHERAPY; META ANALYSIS (TOPIC); MINIMALLY INVASIVE SURGERY; OVARY CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALPINGECTOMY; SCREENING TEST; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX CANCER; UTERINE POWER MORCELLATION; ENDOMETRIAL NEOPLASMS; GENITAL NEOPLASMS, FEMALE; MEDICAL RESEARCH; OVARIAN NEOPLASMS; PATHOLOGY; TRENDS; UTERINE CERVICAL NEOPLASMS;

BIOMEDICAL RESEARCH; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; OVARIAN NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84927550353     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2015.26.2.156     Document Type: Review

References (57)

1. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: a NRG Oncology-Gynecologic Oncology Group study. Ann Oncol 2014;25(Supplement 4):LBA26.
2. Symonds P, Gourley C, Davidson S, West C, Dive C, Paul J, et al. CIRCCA: a randomised double blindphase II trial of carboplatin-paclitaxel plus cediranib versuscarboplatin-paclitaxel plus placebo inmetastatic/recurrent cervical cancer (CRUK GRANT REF: C1256/ A11416). Ann Oncol 2014;25(Supplement 4):LBA25-PR.
3. Hinrichs CS, Stevanovic S, Draper L, Somerville R, Wunderlich J, Restifo NP, et al. HPV-targeted tumor-infiltrating lymphocytes for cervical cancer. J Clin Oncol 2014;32(18 Supplement):LBA3008.
4. Sugiyama T, Fujiwara K, Ohashi Y, Yokota H, Hatae M, Ohno T, et al. Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study. Ann Oncol 2014;25:1011-1017.
5. Noda K, Ohashi Y, Okada H, Ogita S, Ozaki M, Kikuchi Y, et al. Randomized phase II study of immunomodulator Z-100 in patients with stage IIIB cervical cancer with radiation therapy. Jpn J Clin Oncol 2006;36:570-577.
6. Noda K, Ohashi Y, Sugimori H, Ozaki M, Niibe H, Ogita S, et al. Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: treatment with immunomodulator, more is not better. Gynecol Oncol 2006;101:455-463.
7. Society of Gynecologic Oncology. Women's Cancer News. FDA panel approves primary HPV screening tool [Internet]. Irving, TX: Multibriefs; 2014 [cited 2015 Jan 28]. Available from: http://multibriefs.com/briefs/SGO/SGO122914.php.
8. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013;121:829-846.
9. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011;12:880-890.
10. Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011;135:468-475.
11. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-532.
12. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-1597.
13. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-1772.
14. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78-88.
15. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:672-682.
16. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-257.
17. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014;15:172-183.
18. Landrum LM, Nugent EK, Zuna RE, Syzek E, Mannel RS, Moore KN, et al. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol 2014;132:50-54.
19. McMeekin DS, Filiaci VL, Aghajanian C, Cho J, Kim JW, DiSilvestro PA, et al. Randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/ carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gynecologic Oncology Group trial. Gynecol Oncol 2014;134:438.
20. Edelson MI, Chen LM, Burke WM; Society of Gynecologic Oncology Clinical Practice Committee. Postoperative radiation therapy for endometrial cancer: where do we go from here? Pract Radiat Oncol 2014;4:145-146.
21. Park JY, Park SK, Kim DY, Kim JH, Kim YM, Kim YT, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol 2011;122:255-259.
22. Kho KA, Nezhat CH. Evaluating the risks of electric uterine morcellation. JAMA 2014;311:905-906.
23. Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One 2012;e50058:7.
24. Society of Gynecologic Oncology. SGO position statement: morcellation [Internet]. Chicago, IL: Society of Gynecologic Oncology; 2014 [cited 2015 Mar 9]. Available from: https://www.sgo.org/newsroom/position-statements-2/morcellation/.
25. Society of Gynecologic Oncology. Statement of the Society of Gynecologic Oncology to the Food and Drug Administration's Obstetrics and Gynecology Medical Devices Advisory Committee concerning safety of laparoscopic power morcellation [Internet]. Chicago, IL: Society of Gynecologic Oncology; 2014 [cited 2015 Mar 9]. Available from: https://www.sgo.org/wp-content/uploads/2014/04/ SGO-Testimony-to-FDA-on-Power-Morcellation-FINAL.pdf.
26. Hagemann IS, Hagemann AR, LiVolsi VA, Montone KT, Chu CS. Risk of occult malignancy in morcellated hysterectomy: a case series. Int J Gynecol Pathol 2011;30:476-483.
27. Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990;162:968-974.
28. Patient safety must be a priority in all aspects of care. Lancet Oncol 2014;15:123.
29. Goff BA. SGO not soft on morcellation: risks and benefits must be weighed. Lancet Oncol 2014;15:e148.
30. US Food and Drug Administration. FDA news release: FDA dis-courages use of laparoscopic power morcellation for removal of uterus or uterine fibroids [Internet]. Silver Spring, MD: US Food and Drug Administration; 2014 [cited 2015 Mar 9]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393689.htm.
31. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134.
32. Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol 2014;133:362-369.
33. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-861.
34. Curigliano G. From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26-30th September 2014. Ecancer-medicalscience 2014;8:472.
35. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015;16:87-97.
36. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014;15:1207-1214.
37. Suh DH, Kim JW, Kang S, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2013. J Gynecol Oncol 2014;25: 236-48.
38. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013;49:2972-2978.
39. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, et al. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res 2015 Jan 14 [Epub]. http://dx.doi.org/10.1158/1078-0432.CCR-14-2565.
40. Pennington KP, Swisher EM. Hereditary ovarian cancer: beyond the usual suspects. Gynecol Oncol 2012;124:347-353.
41. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20:764-775.
42. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014;32:3374-3382.
43. Liu J, Matulonis UA. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res 2014;20:5150-5156.
44. Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, et al. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst 2014;106:dju029.
45. Gourley C, McCavigan A, Perren T, Paul J, Michie CO, Churchman M, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol 2014;32(15 Supplement):5502.
46. Winterhoff BJ, Kommoss S, Oberg AL, Wang C, Riska SM, Konecny GE, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. J Clin Oncol 2014;3215 Supplement:5509.
47. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
48. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer: shifting the paradigm. Hum Pathol 2011;42:918-931.
49. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Front Oncol 2014;4:21.
50. Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol 2013;129:448-451.
51. Findley AD, Siedhoff MT, Hobbs KA, Steege JF, Carey ET, McCall CA, et al. Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril 2013;100:1704-1708.
52. Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015;107:dju410.
53. Narod SA. Salpingectomy to prevent ovarian cancer: a counter-currents series. Curr Oncol 2013;20:145-147.
54. Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, et al. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol 2015;125:338-345.
55. Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast 2013;22:1094-1100.
56. Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer.N Engl J Med 2015;372:436-46.
57. Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Lang I, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107-118.